Education
About Us
Working with TipRanks
Follow Us
OncoZenge AB (DE:8LY)
FRANKFURT:8LY
8LY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.26 - €0.99
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.08M
Enterprise Value€69.02M
Total Cash (Recent Filing)kr3.86M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding11,713,244
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.26 and its highest was €0.99 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €5.08M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is May 20, 2025 which is in 27 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on Feb 20, 2025. The company reported -€0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.02.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 11,713,244 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.583%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
---
Company Description
OncoZenge AB
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed better pain relief compared with standard therapy. It focuses to implement a phase 3 development program as a basis for regulatory approvals and product launches.
---
Technical Analysis
Biosergen AB
―
Modus Therapeutics Holding AB
―
Spago Nanomedical AB
―
CombiGene AB
―
Sprint Bioscience AB
―
---